685 related articles for article (PubMed ID: 33296726)
1. Exosome-mediated delivery of antisense oligonucleotides targeting α-synuclein ameliorates the pathology in a mouse model of Parkinson's disease.
Yang J; Luo S; Zhang J; Yu T; Fu Z; Zheng Y; Xu X; Liu C; Fan M; Zhang Z
Neurobiol Dis; 2021 Jan; 148():105218. PubMed ID: 33296726
[TBL] [Abstract][Full Text] [Related]
2. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
[TBL] [Abstract][Full Text] [Related]
3. Biomimetic nanodecoys deliver cholesterol-modified heteroduplex oligonucleotide to target dopaminergic neurons for the treatment of Parkinson's disease.
Huang S; Li YJ; Wu JY; Hao XY; Xu WJ; Tang YC; Zhou M; Zhang JC; Luo S; Xiang DX
Acta Biomater; 2024 Mar; 177():316-331. PubMed ID: 38244661
[TBL] [Abstract][Full Text] [Related]
4. C-terminal α-synuclein truncations are linked to cysteine cathepsin activity in Parkinson's disease.
McGlinchey RP; Lacy SM; Huffer KE; Tayebi N; Sidransky E; Lee JC
J Biol Chem; 2019 Jun; 294(25):9973-9984. PubMed ID: 31092553
[TBL] [Abstract][Full Text] [Related]
5. Visualization of early oligomeric α-synuclein pathology and its impact on the dopaminergic system in the (Thy-1)-h[A30P]α-syn transgenic mouse model.
Behere A; Thörnqvist PO; Winberg S; Ingelsson M; Bergström J; Ekmark-Lewén S
J Neurosci Res; 2021 Oct; 99(10):2525-2539. PubMed ID: 34292621
[TBL] [Abstract][Full Text] [Related]
6. Rapid Induction of Dopaminergic Neuron Loss Accompanied by Lewy Body-Like Inclusions in A53T BAC-SNCA Transgenic Mice.
Okuda S; Uemura N; Sawamura M; Taguchi T; Ikuno M; Uemura MT; Yamakado H; Takahashi R
Neurotherapeutics; 2022 Jan; 19(1):289-304. PubMed ID: 34935120
[TBL] [Abstract][Full Text] [Related]
7. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
[TBL] [Abstract][Full Text] [Related]
8. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.
Castro-Sánchez S; García-Yagüe ÁJ; López-Royo T; Casarejos M; Lanciego JL; Lastres-Becker I
Glia; 2018 Aug; 66(8):1752-1762. PubMed ID: 29624735
[TBL] [Abstract][Full Text] [Related]
9. A calcineurin- and NFAT-dependent pathway is involved in α-synuclein-induced degeneration of midbrain dopaminergic neurons.
Luo J; Sun L; Lin X; Liu G; Yu J; Parisiadou L; Xie C; Ding J; Cai H
Hum Mol Genet; 2014 Dec; 23(24):6567-74. PubMed ID: 25051958
[TBL] [Abstract][Full Text] [Related]
10. Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.
Frahm S; Melis V; Horsley D; Rickard JE; Riedel G; Fadda P; Scherma M; Harrington CR; Wischik CM; Theuring F; Schwab K
Behav Brain Res; 2018 Feb; 339():153-168. PubMed ID: 29180135
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson's disease in rodent brains.
Bérard M; Martínez-Drudis L; Sheta R; El-Agnaf OMA; Oueslati A
Mol Neurodegener; 2023 Nov; 18(1):91. PubMed ID: 38012703
[TBL] [Abstract][Full Text] [Related]
12. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
Sharma N; Rao SP; Kalivendi SV
Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
[TBL] [Abstract][Full Text] [Related]
13. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
[TBL] [Abstract][Full Text] [Related]
14. GV-971 attenuates α-Synuclein aggregation and related pathology.
Yu Z; Yang Y; Chan RB; Shi M; Stewart T; Huang Y; Liu Z; Lan G; Sheng L; Tian C; Yang D; Zhang J
CNS Neurosci Ther; 2024 Feb; 30(2):e14393. PubMed ID: 37563872
[TBL] [Abstract][Full Text] [Related]
15. Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Familial Parkinson's Disease Patients Display α-Synuclein Pathology and Abnormal Mitochondrial Morphology.
Diao X; Wang F; Becerra-Calixto A; Soto C; Mukherjee A
Cells; 2021 Sep; 10(9):. PubMed ID: 34572052
[TBL] [Abstract][Full Text] [Related]
16. Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease.
Sato H; Arawaka S; Hara S; Fukushima S; Koga K; Koyama S; Kato T
J Neurosci; 2011 Nov; 31(46):16884-94. PubMed ID: 22090514
[TBL] [Abstract][Full Text] [Related]
17. Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease.
Spencer B; Trinh I; Rockenstein E; Mante M; Florio J; Adame A; El-Agnaf OMA; Kim C; Masliah E; Rissman RA
Neurobiol Dis; 2019 Jul; 127():163-177. PubMed ID: 30849508
[TBL] [Abstract][Full Text] [Related]
18. The Parkinson's disease-related protein DJ-1 protects dopaminergic neurons in vivo and cultured cells from alpha-synuclein and 6-hydroxydopamine toxicity.
Batelli S; Invernizzi RW; Negro A; Calcagno E; Rodilossi S; Forloni G; Albani D
Neurodegener Dis; 2015; 15(1):13-23. PubMed ID: 25500798
[TBL] [Abstract][Full Text] [Related]
19. Lycorine, a natural alkaloid, promotes the degradation of alpha-synuclein via PKA-mediated UPS activation in transgenic Parkinson's disease models.
Zhu Q; Zhuang XX; Chen JY; Yuan NN; Chen Y; Cai CZ; Tan JQ; Su HX; Lu JH
Phytomedicine; 2021 Jul; 87():153578. PubMed ID: 34038839
[TBL] [Abstract][Full Text] [Related]
20. Parkinson's Disease Derived Exosomes Aggravate Neuropathology in SNCA*A53T Mice.
Huang Y; Liu Z; Li N; Tian C; Yang H; Huo Y; Li Y; Zhang J; Yu Z
Ann Neurol; 2022 Aug; 92(2):230-245. PubMed ID: 35596947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
